Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic

Mégane Vernon1,2, Bernard Lambert1,2,3, Matthieu Meryet-Figuière1,2

  • 1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.

Insights

Novel microRNAs (miRNAs) like miR-3622b-5p show potent anti-cancer effects against chemoresistant ovarian cancer. Combining targeted therapies mimicking these miRNA actions offers promising new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian carcinoma is a leading cause of cancer-related death among gynecologic malignancies.
  • Chemoresistance significantly limits treatment efficacy in advanced ovarian cancer.
  • MicroRNAs (miRNAs) regulate gene expression and cellular phenotypes, offering potential therapeutic targets.

Purpose of the Study:

  • To identify novel miRNAs with cytotoxic effects in chemoresistant ovarian cancer cells.
  • To elucidate the molecular mechanisms of action for identified miRNAs.
  • To explore potential combination therapies based on miRNA functions.

Main Methods:

  • Phenotype-based miRNA screening combined with real-time cell monitoring.
  • Functional assays to assess apoptosis, chemosensitization, and antimigratory effects.
  • In vitro studies using ovarian cancer cell lines and patient-derived tumor organoids.

Main Results:

  • miR-3622b-5p demonstrated significant cytotoxic effects by inducing apoptosis via Bcl-xL and EGFR/BIM pathways.
  • miR-3622b-5p sensitized cells to cisplatin and inhibited migration by targeting LIMK1 and NOTCH1.
  • Combination therapy with EGFR inhibitors and BH3-mimetics effectively reduced cell viability in ovarian cancer models.

Conclusions:

  • miR-3622b-5p exhibits broad antitumor activities against ovarian cancer.
  • Targeting pathways modulated by miR-3622b-5p with pharmacologic inhibitors shows therapeutic potential.
  • This study validates phenotype-based miRNA screening for discovering novel therapeutic strategies and drug combinations in ovarian carcinoma.